CRISPR-Cas9 as a gene-editing tool — Doudna and Charpentier
2012 AD · Transmission: Global
BiologyMethodNorth American
Doudna and Charpentier adapt the bacterial CRISPR-Cas9 immune system as a precise, low-cost genome-editing tool. It allows editing any gene in any organism. In 2024 the first CRISPR therapy in humans is approved (Casgevy, sickle cell disease).
InstitutionUC Berkeley / Institut Pasteur / Umeå University
Historical regionUnited States / France
Primary sourceJinek, M. et al. — "A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity" (Science, 2012)